Please login to the form below

Not currently logged in
Email:
Password:

Evotec

This page shows the latest Evotec news and features for those working in and with pharma, biotech and healthcare.

LSTM and LifeArc announce partnership and research fund to tackle infectious diseases

LSTM and LifeArc announce partnership and research fund to tackle infectious diseases

As well as LifeArc, core partners of iiCON, a £250m programme, include Unilever, Evotec, Liverpool University Hospitals Foundation Trust, the University of Liverpool and Infex Therapeutics.

Latest news

More from news
Approximately 18 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Alzheimer’s disease: the search for a cure Alzheimer’s disease: the search for a cure

    The companies, Abbvie, Astex Pharmaceuticals, Eisai, Johnson &Johnson, Lilly, MSD and Takeda, Evotec and Charles River, participate in research projects alongside academic scientists.

  • A snapshot of… Exscientia A snapshot of… Exscientia

    We’ve also signed numerous major pharma collaborations with companies including Roche, Celgene, Sanofi, GSK and Evotec, estimated to be worth over $1bn in milestones and royalties.

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Last month, Johnson &Johnson Innovation, Takeda and Evotec became the latest pharma research groups to join the initiative, alongside existing strategic partners AbbVie, Astex Pharmaceuticals, Eisai, Lilly and MSD. ... We’re excited to welcome Johnson

  • Pharma deals continue to slide Pharma deals continue to slide

    For example, Evotec, the German small molecule development company, is acquiring for $300m the US preclinical development company, Aptuit. ... 400. Aptuit (US). Evotec (DE). Company acquisition. Drug discovery and development to IND submission including

  • Deal Watch December 2016 Deal Watch December 2016

    320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for neurodegenerative diseases. ... upfront. And although the upfronts are a modest percentage of the headline figure, ranging from < 1% (BioInvent) to 15%

More from intelligence
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....